CTLA4 and delirium: ICIs, including anti‐PD‐1 and anti‐CTLA‐4 agents, are increasingly recognized to induce various neuropsychiatric immune‐related adverse events, including encephalitis, aseptic meningitis, and, less frequently, delirium [4, 5, 9].